Stress Relief Management in Farmigton Hills, MI - Social Worker

Stress Relief Management is a mental health clinic (Social Worker) in Farmigton Hills, Michigan. The current practice location for Stress Relief Management is 30500 Northwestern Hwy.,, #316b, Farmigton Hills, Michigan. For appointments, you can reach them via phone at (248) 539-8781. The mailing address for Stress Relief Management is 30500 Northwestern Hwy.,, #316b, Farmigton Hills, Michigan and phone number is () -.

Stress Relief Management is licensed to practice in Michigan (license number 6801085997) and its NPI number is 1619206521. This medical practice does not participate in medicare program and thus may not accept your medicare insurance. You may check if they accept your insurance at (248) 539-8781.

Contact Information

	Stress Relief Management
	30500 Northwestern Hwy., #316b Farmigton Hills MI 48334
	(248) 539-8781
	Not Available

Mental Health Clinic Profile

Full Name	Stress Relief Management
Speciality	Social Worker
Location	30500 Northwestern Hwy.,, Farmigton Hills, Michigan
Authorized Official Name and Position	Izabella Gorivodskaya (SOCIAL WORKER)
Authorized Official Contact	2485398781
Accepts Medicare Insurance	This clinic does not participate in Medicare Program.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Stress Relief Management 30500 Northwestern Hwy., #316b Farmigton Hills MI 48334 Ph: () -	Stress Relief Management 30500 Northwestern Hwy., #316b Farmigton Hills MI 48334 Ph: (248) 539-8781

NPI Details:

NPI Number	1619206521
Provider Enumeration Date	12/24/2009
Last Update Date	12/24/2009

Medical Identifiers

Medical identifiers for Stress Relief Management such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1619206521	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
104100000X	Social Worker	6801085997 (Michigan)	Primary

News Archive

Euthymics's EB-1010 effective in treatment of major depressive disorder: Study

Euthymics Bioscience, Inc. today will present Phase II clinical data demonstrating that its lead product candidate EB-1010, a next-generation antidepressant, is effective for treating major depressive disorder (MDD) based on multiple standard measures of outcome for depression. EB-1010 also improved measures of anhedonia, a hallmark symptom of MDD, which is characterized by the inability to experience pleasure.

MEDfx announces Direct Project pilot to demonstrate health information exchange among providers

MEDfx Corporation today announced a Direct Project pilot that demonstrates health information exchange among providers using a combination of the standards and protocols supported by the Direct Project and the FHA CONNECT Gateway. MEDfx is participating in, and is a contributor to, the nationally-sponsored Direct Project under the Office of the National Coordinator of Health IT.

Women with recurrent miscarriages can have successful pregnancy with supportive care

For women who have multiple miscarriages, the pain of repeated loss is often compounded by another reality. The causes behind miscarriage are complex and often difficult to identify, and even those conditions and associations proposed as causes are poorly understood.

Potential biomarkers of coagulopathy and disease severity in COVID-19

Scientists have investigated the presence of specific biomarkers in hospitalized COVID-19 patients

Stress Relief Management - Mental Health Clinic in Farmigton Hills, MI